Latest Insider Transactions at Biogen Inc. (BIIB)
This section provides a real-time view of insider transactions for Biogen Inc. (BIIB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOGEN INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOGEN INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 08
2024
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
253
-5.12%
|
$60,720
$240.3 P/Share
|
|
Feb 08
2024
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
788
+13.75%
|
-
|
|
Feb 08
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-8.08%
|
$153,120
$240.3 P/Share
|
|
Feb 08
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,101
+21.02%
|
-
|
|
Feb 08
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-5.08%
|
$183,600
$240.3 P/Share
|
|
Feb 08
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,335
+13.42%
|
-
|
|
Feb 02
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
634
-13.4%
|
$155,330
$245.93 P/Share
|
|
Feb 01
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
561
-10.6%
|
$138,567
$247.83 P/Share
|
|
Feb 01
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,828
+25.67%
|
-
|
|
Dec 11
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
110
-3.08%
|
$27,280
$248.0 P/Share
|
|
Dec 08
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-5.45%
|
$49,234
$239.29 P/Share
|
|
Dec 08
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
426
+10.13%
|
-
|
|
Dec 08
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
170
-3.93%
|
$40,630
$239.29 P/Share
|
|
Dec 08
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
351
+7.51%
|
-
|
|
Sep 05
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
431
-11.39%
|
$115,939
$269.43 P/Share
|
|
Sep 01
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-17.57%
|
$215,469
$267.17 P/Share
|
|
Sep 01
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,668
+26.65%
|
-
|
|
Sep 01
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,704
-10.08%
|
$721,968
$267.17 P/Share
|
|
Sep 01
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,285
+16.46%
|
-
|
|
Jul 03
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
81
-2.7%
|
$22,842
$282.87 P/Share
|
|
Jun 30
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-2.98%
|
$34,648
$284.85 P/Share
|
|
Jun 30
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
252
+5.8%
|
-
|
|
Jun 30
2023
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
244
-3.82%
|
$69,296
$284.85 P/Share
|
|
Jun 30
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
504
+7.31%
|
-
|
|
Jun 30
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
153
-4.84%
|
$43,452
$284.85 P/Share
|
|
Jun 30
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
315
+9.07%
|
-
|
|
Jun 26
2023
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+4.87%
|
-
|
|
Jun 26
2023
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+13.7%
|
-
|
|
Jun 26
2023
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+4.54%
|
-
|
|
Jun 26
2023
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+23.62%
|
-
|
|
Jun 26
2023
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+15.71%
|
-
|
|
Jun 26
2023
|
Susan Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+40.35%
|
-
|
|
Jun 26
2023
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,580
+5.98%
|
-
|
|
Apr 28
2023
|
Ginger Gregory EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,681
-24.02%
|
$804,300
$300.0 P/Share
|
|
Apr 04
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
91
-3.1%
|
$25,207
$277.11 P/Share
|
|
Mar 31
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
116
-1.99%
|
$32,248
$278.03 P/Share
|
|
Mar 31
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
239
+3.95%
|
-
|
|
Mar 28
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
568
-16.66%
|
$153,360
$270.06 P/Share
|
|
Mar 02
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
687
-9.17%
|
$184,116
$268.75 P/Share
|
|
Mar 02
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
297
+7.71%
|
-
|
|
Feb 17
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-4.37%
|
$64,774
$278.38 P/Share
|
|
Feb 17
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
480
+7.92%
|
-
|
|
Feb 17
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-3.82%
|
$41,978
$278.38 P/Share
|
|
Feb 17
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+10.43%
|
-
|
|
Feb 17
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-6.67%
|
$66,164
$278.38 P/Share
|
|
Feb 17
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
512
+11.76%
|
-
|
|
Feb 17
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,310
-14.73%
|
$364,180
$278.38 P/Share
|
|
Feb 17
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,561
+20.15%
|
-
|
|
Feb 17
2023
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
371
-6.76%
|
$103,138
$278.38 P/Share
|
|
Feb 17
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
767
+11.53%
|
-
|